Venetoclax

Venetoclax 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma、Leukemia, Lymphocytic, Chronic, B-Cell、Leukemia, Chronic Lymphocytic、Small-Cell Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Venetoclax 研究

• Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

  II 期招募中美国NCT05442216

• A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  I 期招募中美国NCT05735184

• Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

  I 期招募中美国NCT06429449

• Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

  早期 I 期招募中美国NCT05553782

• Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

  不适用招募中中国NCT06386302

• A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

  I 期招募中美国NCT06397027

• Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

  II 期招募中美国NCT05183854

• A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

  I 期招募中美国NCT05834244

• A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

  II 期招募中美国NCT05365035

• Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

  II 期招募中美国NCT05910801

• A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  III 期招募中美国澳大利亚法国GreeceNCT06428019

• Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  II 期招募中美国NCT06649812

• A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML

  不适用招募中中国NCT06329999

• CAV Regimen for R/R AML

  II 期招募中中国NCT05657639

• A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

  II 期招募中美国NCT06561074

• Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial

  不适用招募中意大利NCT07420790

• Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML

  I 期 / II 期招募中中国NCT06757855

• Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

  II 期招募中中国NCT06221683

• This Study Aims to Improve the Stratification of Patients With Acute Myeloid Leukemia to Enable More Personalized and Effective Treatments, and to Identify and Functionally Validate, at the Single-cell Level, Biomarkers That Can Predict Response to Venetoclax.

  不适用招募中意大利NCT07874100

• Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

  I 期 / II 期招募中美国NCT03661307

• Venetoclax Basket Trial for High Risk Hematologic Malignancies

  I 期招募中美国NCT05292664

• Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

  I 期招募中比利时NCT05506332

• Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

  I 期 / II 期招募中中国NCT06082934

• A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients

  II 期招募中中国NCT06928376

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。